New Omega-3 Formula Launches in Las Vegas
The supplement aims to improve brain nutrient absorption, with clinical trials for the formula scheduled for late 2026.
Updated on Oct. 26, 2026 in Alzheimer’s
Live Poll
Is now a good time to pay more for supplements promising better nutrient absorption?
SourceOne Global Partners has unveiled a new omega-3 supplement called LysOmega, which aims to improve how the brain and eyes absorb DHA and EPA. The formula, which took four years to develop, was introduced to the local market at the SupplySide Global 2026 event.
Why it matters
Optimal delivery of fatty acids to the brain remains a significant hurdle in long-term cognitive health research. This new formulation seeks to overcome existing absorption barriers, though clinical confirmation of its efficacy in human subjects is still pending.
A Phase I study demonstrated that the VESIsorb delivery system increases omega-3 absorption up to 26-fold. The system has 35 years of prior commercial use, and a dedicated clinical trial is scheduled for late 2026.
The players
SourceOne Global Partners
The company responsible for the development and launch of the LysOmega supplement.
Michael Davidson
The professional leading the upcoming human clinical trial for the new omega-3 formula.
The details
LysOmega combines fish oil-derived DHA and EPA with phospholipids and choline. The manufacturer claims the VESIsorb system uses small droplets to improve bioavailability and help fatty acids cross the blood-brain and blood-retina barriers. The product reached the public following a four-year development cycle. A human clinical trial, led by Michael Davidson, is currently set to begin in Q4 2026 to assess circulating DHA and EPA levels in patients.
Timeline
October 26-30, 2026: SupplySide Global 2026 event took place in Las Vegas.
Q4 2026: A human clinical trial for the new formulation is scheduled to begin.
Beyond the Strip
This launch follows the industry trend of developing targeted delivery systems for nutrients intended to mitigate neurological risk factors. It mirrors broader efforts to improve supplement efficacy for populations with high-risk genetic markers like APOE4.
Residents attending the SupplySide Global event have had the opportunity to review the formulation and its development history. While the supplement is now available, local consumers should wait for the results of the 2026 clinical trials to understand its specific health impacts.
The takeaway
While the new formula promises significant improvements in nutrient absorption, its efficacy for cognitive health is currently theoretical. Residents should monitor the 2026 clinical trial results before drawing conclusions about potential health benefits.
What happens next
A human clinical trial is scheduled to begin in Q4 2026 to evaluate the supplement's impact on circulating DHA and EPA levels.
Further reading
Learn more about local research and health trends on our Alzheimer’s page.
Source note: This article includes information reported by Nutritioninsight.
Live Poll
Is now a good time to pay more for supplements promising better nutrient absorption?
